Baidu
map

Nature Metabolism:“换血抗衰老”奠基人最新研究:老年血液会迅速诱导年轻个体未老先衰

2022-08-06 甲遇庚 “生物世界”公众号

该研究通过“异体共生”单次血液交换证明老年小鼠血液诱导年轻动物的细胞和组织衰老;但如果在血液交换前用抗衰老药物治疗老年动物,就会减弱老年血液对年轻小鼠的促衰老影响。

实现“返老还童”一直是抗衰老领域科学家们的终极梦想。早在2005年,加州大学伯克利分校的 Irina Conboy 等人就在 Nature 发表论文,通过“异体共生”(人工建立年轻小鼠和老年小鼠连体“双胞胎”,使它们共享血液、器官和环境)的实验发现,年轻小鼠的血液能使老年小鼠肌肉组织和肝细胞再生,从而逆转了衰老的迹象。详细:换血可让人返老还童?Nat Commun:新研究简化小鼠换血方法

这项研究引发了一阵研究热潮,从那时起,科学家们开始研究年轻人的血液中是否含有某些特殊分子,可以作为人类的“青春之泉”,从而实现“返老还童”。

而近日,Irina Conboy 教授发表的一项最新研究则“反其道行之”,通过年轻小鼠与老年小鼠交换血液来探索衰老的机制。

2022年7月28日,Irina Conboy 教授团队等在 Nature Metabolism 期刊上发表了题为:Systemic induction of senescence in young mice after single heterochronic blood exchange 的论文。

该研究通过“异体共生”单次血液交换证明老年小鼠血液诱导年轻动物的细胞和组织衰老;但如果在血液交换前用抗衰老药物治疗老年动物,就会减弱老年血液对年轻小鼠的促衰老影响。

该研究提出了一种新范式——衰老过程可以由全身性衰老诱导来加速,而不仅仅是通过生物年龄的增长。

Irina Conboy 教授

随着时间推移,每个生命都将走向衰老,而衰老是许多慢性病的最大风险因素。虽然细胞衰老和机体衰老是两个不同的概念,但二者有着密切的联系。

当正常细胞暴露于复杂的应激环境下,就会产生包括基因组损伤、线粒体功能障碍、代谢失调等衰老诱导因子的衰老细胞(SnC)。这些衰老细胞也会随着年龄的增长而增加,并释放出衰老相关分泌表型(SASP)。SASP会以旁分泌的方式促进与年龄有关的表型和病理变化,但老年哺乳动物的生理性衰老细胞对其全身性的影响仍是未知的。

在这项新研究中,为了确定老年全身性环境的促衰老作用,研究人员在年轻和老年小鼠的血清与人类个体血浆中培养了非衰老的原代人和小鼠细胞。

通过小鼠实验发现,与年轻小鼠(4月龄)的血清相比,老年小鼠(32月龄)的血清增加了衰老上调基因 Cdkn2a、Cdkn1a 和 SASP 因子 IL-6 和 Mmp3 的表达,降低了衰老基因 Lmnb1 的表达,衰老相关β-半乳糖苷酶(SA-β-gal)活性上调,以及细胞增殖减少。

值得注意的是,用老年小鼠血清处理的真皮成纤维细胞中诱导的衰老表型与年轻和老年小鼠血清50:50混合物诱导的衰老表型相似。这表明老年小鼠血清在实验中占主导地位。衰老表型可以通过来自老年小鼠的血清转移到非衰老真皮成纤维细胞中。

研究人员发现,衰老循环环境的衰老转移似乎在小鼠和人类之间也是保守的,但这种转移是细胞和组织特异性的,因为它不涉及所有细胞类型(例如,肺成纤维细胞或乳腺上皮细胞)或所有标志物。当用来自年轻(20-30 岁)或老年(60-70 岁)个体的人血浆培养人原代肾上皮细胞时,来自老年个体的血浆在6天内诱导了多种衰老上调基因的表达增加。

为了确定衰老的全身性环境是否会在体内引起反式衰老反应,研究人员随后进行了老年小鼠(22-24月龄)和年轻小鼠(3月龄)的异体慢性血液交换。实验表明,老年小鼠的血液诱导了年轻小鼠的细胞和组织衰老,包括肝脏、肾脏和骨骼肌细胞的老化、肝纤维化、近端肾小管损伤、肌肉力量下降等。

研究人员还发现,如果在血液交换前对老年小鼠使用抗衰老药物达沙替尼加槲皮素(Senolytics类药物,能够靶向清除衰老细胞)和 ABT263(一种可诱导细胞凋亡的小分子Bcl-2抑制剂)治疗,就会减弱年轻小鼠中衰老卫星细胞和衰老肌肉间质细胞的数量,防止年轻小鼠出现衰老症状。详细见:eBioMedicine:口服抗衰老药物,恢复人体抗衰老蛋白

此外,当老年小鼠获得年轻小鼠血液后,肌肉内脂质和纤维化的积累减少,疲劳性降低,肌肉耐力提高,这与以前年轻小鼠血液逆转衰老的研究结果一致。

然而,与接受载体处理老年小鼠血液的老年动物相比,接受 ABT263 治疗的老年小鼠血液的老年动物并未降低衰老标志物,也没有发生肌肉力量丧失、肾损伤、肝纤维化和缺乏身体耐力。这些发现表明,老年个体的全身环境中还存在与独立于衰老细胞的其他因素。因此,这意味着清除衰老细胞与年轻全身性环境对年轻小鼠组织功能具有协同作用。

总的来说,该研究表明哺乳动物的衰老似乎是由包括衰老相关的分泌表型在内的全身性因素驱动的,减少或消除这些因素有望产生延长健康寿命的新治疗策略。

原始出处:

Jeon, O.H., Mehdipour, M., Gil, TH. et al. Systemic induction of senescence in young mice after single heterochronic blood exchange. Nat Metab (2022). https://doi.org/10.1038/s42255-022-00609-6.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885924, encodeId=9f9a188592496, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 11 12:23:14 CST 2023, time=2023-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736509, encodeId=0c7f1e36509da, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Mon Oct 31 18:23:14 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888453, encodeId=23c2188845315, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 01 12:23:14 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897046, encodeId=2f83189e04601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 24 02:23:14 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577294, encodeId=907015e72945f, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598174, encodeId=9f3815981e4bd, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236968, encodeId=99851236968a7, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236967, encodeId=a156123696e89, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:40 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885924, encodeId=9f9a188592496, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 11 12:23:14 CST 2023, time=2023-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736509, encodeId=0c7f1e36509da, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Mon Oct 31 18:23:14 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888453, encodeId=23c2188845315, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 01 12:23:14 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897046, encodeId=2f83189e04601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 24 02:23:14 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577294, encodeId=907015e72945f, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598174, encodeId=9f3815981e4bd, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236968, encodeId=99851236968a7, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236967, encodeId=a156123696e89, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:40 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-10-31 贵阳
  3. [GetPortalCommentsPageByObjectIdResponse(id=1885924, encodeId=9f9a188592496, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 11 12:23:14 CST 2023, time=2023-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736509, encodeId=0c7f1e36509da, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Mon Oct 31 18:23:14 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888453, encodeId=23c2188845315, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 01 12:23:14 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897046, encodeId=2f83189e04601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 24 02:23:14 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577294, encodeId=907015e72945f, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598174, encodeId=9f3815981e4bd, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236968, encodeId=99851236968a7, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236967, encodeId=a156123696e89, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:40 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2023-05-01 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1885924, encodeId=9f9a188592496, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 11 12:23:14 CST 2023, time=2023-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736509, encodeId=0c7f1e36509da, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Mon Oct 31 18:23:14 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888453, encodeId=23c2188845315, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 01 12:23:14 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897046, encodeId=2f83189e04601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 24 02:23:14 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577294, encodeId=907015e72945f, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598174, encodeId=9f3815981e4bd, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236968, encodeId=99851236968a7, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236967, encodeId=a156123696e89, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:40 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2023-05-24 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1885924, encodeId=9f9a188592496, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 11 12:23:14 CST 2023, time=2023-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736509, encodeId=0c7f1e36509da, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Mon Oct 31 18:23:14 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888453, encodeId=23c2188845315, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 01 12:23:14 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897046, encodeId=2f83189e04601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 24 02:23:14 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577294, encodeId=907015e72945f, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598174, encodeId=9f3815981e4bd, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236968, encodeId=99851236968a7, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236967, encodeId=a156123696e89, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:40 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1885924, encodeId=9f9a188592496, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 11 12:23:14 CST 2023, time=2023-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736509, encodeId=0c7f1e36509da, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Mon Oct 31 18:23:14 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888453, encodeId=23c2188845315, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 01 12:23:14 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897046, encodeId=2f83189e04601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 24 02:23:14 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577294, encodeId=907015e72945f, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598174, encodeId=9f3815981e4bd, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236968, encodeId=99851236968a7, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236967, encodeId=a156123696e89, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:40 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-08-08 闆锋旦
  7. [GetPortalCommentsPageByObjectIdResponse(id=1885924, encodeId=9f9a188592496, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 11 12:23:14 CST 2023, time=2023-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736509, encodeId=0c7f1e36509da, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Mon Oct 31 18:23:14 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888453, encodeId=23c2188845315, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 01 12:23:14 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897046, encodeId=2f83189e04601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 24 02:23:14 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577294, encodeId=907015e72945f, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598174, encodeId=9f3815981e4bd, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236968, encodeId=99851236968a7, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236967, encodeId=a156123696e89, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:40 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1885924, encodeId=9f9a188592496, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Jul 11 12:23:14 CST 2023, time=2023-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1736509, encodeId=0c7f1e36509da, content=<a href='/topic/show?id=a421604e721' target=_blank style='color:#2F92EE;'>#最新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60477, encryptionId=a421604e721, topicName=最新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bd534165494, createdName=贵阳, createdTime=Mon Oct 31 18:23:14 CST 2022, time=2022-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888453, encodeId=23c2188845315, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Mon May 01 12:23:14 CST 2023, time=2023-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897046, encodeId=2f83189e04601, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed May 24 02:23:14 CST 2023, time=2023-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577294, encodeId=907015e72945f, content=<a href='/topic/show?id=d86d1159e36' target=_blank style='color:#2F92EE;'>#Metabolism#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11597, encryptionId=d86d1159e36, topicName=Metabolism)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a6516392333, createdName=1249859em43(暂无昵称), createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598174, encodeId=9f3815981e4bd, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Mon Aug 08 05:23:14 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236968, encodeId=99851236968a7, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:47 CST 2022, time=2022-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236967, encodeId=a156123696e89, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Sat Aug 06 19:32:40 CST 2022, time=2022-08-06, status=1, ipAttribution=)]
    2022-08-06 ms6000000960504356

    不错的文章

    0

相关资讯

基本功测验:这些常见血液细胞形态,你认得哪些?

这些常见血液细胞形态,你不能不认识!

要点解读:血栓性血小板减少性紫癜诊断与治疗中国指南(2022年版)

中华医学会血液学分会血栓与止血学组经过讨论,发布了《血栓性血小板减少性紫癜诊断与治疗中国指南(2022版)》(简称指南)。在本文中,笔者针对指南中重要的更新部分作详细解读。

“星光奕奕-深度解读”血液大咖云集,邀您赴约!

“星光奕奕-深度解读”第二季线上会议,复星凯特生物科技有限公司专注于细胞免疫治疗,致力于治愈肿瘤患者,届时将邀请血液学界享有盛誉的血液大咖,邀您共赴此次盛会!

《治疗性血液成分单采技术标准》专家共识(第2版)

该版《专家共识》应用于指导临床实践2年以来,全国21家医疗机构的相关领域专家不断对其提出修改建议。

急性白血病诊断与治疗3天训练营

中国医学科院 血液学研究所 王迎主任主讲3场血液病诊断核心课程

血HCG和尿HCG,哪个更准确?

验孕棒到底准不准?同房后多久测定HCG为最佳时间?HCG升高一定是怀孕吗?

Baidu
map
Baidu
map
Baidu
map